Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Everest Acquires Rights in Greater China to Lenz’ Vizz for Presbyopia
Everest Medicines, of Shanghai, China, has acquired rights in Greater China to Lenz Therapeutics’ Vizz (LNZ100) eye drops for presbyopia, Lenz reported June 7. Lenz, of San Diego, California, said ...
Formycon’s Aflibercept Biosimilar in Prefilled Syringes Now Available in EU
Germany’s Formycon announced May 19 that its aflibercept (Eylea) biosimilar, known in various territories as Ahzantive and Baiama, was now available in the European Union. It is being introduced in...
Samsung Bioepis Launches Aflibercept Biosimilar Branded Opuviz in EU
Korea’s Samsung Bioepis announced May 29 that it had launched Opuviz, a biosimiliar referencing Eylea (aflibercept), across Europe. The biosimilar is also available in Korea and Canada as Aflivu. H...
Harrow Relaunches Verkazia in the US for Vernal Keratoconjunctivitis
Harrow reported June 10 that it had relaunched Verkazia (cyclosporine ophthalmic emulsion, 0.1%) in the US for the treatment of vernal keratoconjunctivitis (VKC). VKC is a serious allergic eye dise...
AAO Licenses Clinical Practice Guidelines to OpenEvidence Chatbot for Doctors
The American Academy of Ophthalmology reported June 9 that it had licensed the guidance in itsPreferred Practice Patterns and Ophthalmic Technology Assessments to OpenEvidence for its medical AI pl...
Apotex Gains Health Canada Approval for Iheezo Ophthalmic Anesthesia
Toronto’s Apotex announced May 26 that it had secured Health Canada marketing approval for Iheezo (chloroprocaine hydrochloride ophthalmic gel 3%), a topical anesthetic indicated for ocular surface...
Bausch + Lomb Launches Blink Triple Care Preservative Free Drops in US
Bausch + Lomb announced June 1 the US launch of Blink Triple Care Preservative Free eye drops. The lipid- and water-based formula combines a natural oil—to help keep tears from evaporating too quic...
Lupin Gains US FDA Approval for Ranibizumab Biosimilar Branded Ranluspec
India’s Lupin Limited announced June 4 that the US FDA had approved Ranluspec (ranibizumab-hkdz) as an interchangeable biosimilar referencing Lucentis. Lupin said Ranluspec was the only interchange...
Alvotech Resubmits BLA to US FDA for Aflibercept Biosimilar
Alvotech, of Reykjavik, Iceland, reported June 4 that it had resubmitted its biologics license application (BLA) to the US FDA for AVT06, a biosimilar to Eylea (aflibercept). Alvotech said it had a...
Optos Names Alexandre Montague as CEO
UK-based Optos announced June 9 that it had appointed Alexandre Montague as chief executive officer, effective immediately. Optos, a subsidiary of Japan’s Nikon, pioneered ultra-widefield retinal i...
Oculis Scraps DME Eye Drop Program after Phase III Failure
Swiss company Oculis reported May 29 that it would not pursue US FDA approval for OCS-01, its dexamethasone eye drop candidate targeting diabetic macular edema (DME), after the primary endpoint of ...
Outlook Therapeutics Resubmits BLA for Lytenava After Winning Appeal with FDA
Outlook Therapeutics reported June 1 that it had resubmitted its biologics license application (BLA) to the US FDA for Lytenava, its ophthalmic formulation of bevacizumab for the treatment of wet a...
Past News Stories
Rayner Launches New Ophteis Cohesive OVD, Rebrands Line
UK-based Rayner announced June 1 the launch of Ophteis Cohesive, a new ophthalmic viscosurgical device (OVD) developed and manufactured at its biomaterials facility in Portugal. The company said th...
Zeiss, M2care Invest in Maculaser, Developer of Temperature-Controlled Retinal Laser Therapy
Finland-based Maculaser Oy has received a new investment from Zeiss Ventures, the corporate venture capital arm of Germany’s Zeiss Group, and M2care, a European health tech venture studio, as Macul...
Sightpath to Deliver IQity’s Products Through Mobile Platform Under New Partnership
Reno, Nevada-based IQity reported May 21 that it was partnering with Sightpath Medical to deliver its technology to surgeons. IQity is developing eight products expected to launch between 2027 and ...
Luminopia Licenses Amblyopia Therapy to Rohto for Japan Market
Luminopia, of Cambridge, Massachusetts, reported June 2 that it had licensed its pediatric amblyopia treatmentto Rohto Pharmaceutical Co. to develop and commercialize in Japan. Rohto is a Japanese ...
US FDA Leadership Shakeup Continues as Drug Division Chief Exits
The US FDA’s drug evaluation division has another new leader. Michael Davis, MD, PhD, has been named acting director of the Center for Drug Evaluation and Research (CDER), according to the FDA’s we...
Georgia Southern University Gains Funding for State’s First College of Optometry
Georgia Southern University announced May 26 that it had received $29.8 million in state funding to establish the first college of optometry in Georgia. The school said the money will support the r...
SpyGlass Gains Category III CPT Code for Its Drug-Eluting BIM-IOL System
SpyGlass Pharma, of Aliso Viejo, California, reported May 18 that the American Medical Association had approved a new add-on Category III CPT code that will allow surgeons to be reimbursed separate...
Carl Zeiss Meditec Names Bronwyn Brophy O’Connor as CEO
German company Carl Zeiss Meditec reported May 22 that it had appointed Bronwyn Brophy O’Connor as chief executive officer and a member of the management board. Zeiss said O’Connor brings 25 years ...
Q1-2026 Ophthalmic Revenue Roundup for Apellis, Immunocore, STAAR, and Iridex
Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 in its quarterly financial report for Q1-2026 that its net product revenue for Syfovre was $150.7 million, a 15.4 percent increase...
Myopia Management Roundup: Research Includes Study Raising Safety Concerns over Some Red-Light Devices
A laboratory study published this year in JAMA Ophthalmology calls into question the safety of commercially available red-light therapy devices as a treatment option for young myopes. Repeated low-...
Study Links Vitamins B3 and B12 to Lower Risk of Glaucoma
Researchers in the Netherlands recently assessed the link between B vitamin intake and glaucoma. Their findings were published in April in the American Journal of Ophthalmology. B vitamins play an ...
ViaLase Announces First Commercial FLIGHT Procedures in Glaucoma Patients
ViaLase, of Aliso Viejo, California, announced May 26 that surgeons in London and Germany had performed the first commercial procedures using its ViaLuxe Laser System for femtosecond laser image-gu...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.